Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNP-2092 PK and Food Effect in Healthy Subjects
NCT06178718Phase 1Completed
- Sponsor
- TenNor Therapeutics
- Start
- Jun 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rifaquizinone in hyperammonemia and hepatic encephalopathy (HE) (6 arms), sponsored by TenNor Therapeutics. Primary endpoints: Number of Participants With Adverse Events up to 8 days, Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity and 4 more. Started Jun 2016; status: completed.
02
Drugs
rifaquizinone
03
Conditions
hyperammonemiahepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT06178718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06178718.